智通财经APP获悉，云顶新耀(01952)逆市涨超5%，截至发稿，涨4.49%，报46.5港元，成交额1.44亿港元。
消息面上，云顶新耀此前宣布，耐赋康(布地奈德肠溶胶囊)正式获得国家药品监督管理局（NMPA）同意，由附条件批准转为完全批准，用于治疗具有疾病进展风险的原发性免疫球蛋白A肾病（IgAN）成人患者，以减少肾功能损失。新适应症夯实了耐赋康治疗 IgA 肾病一线基石地位，此次完全批准意味着耐赋康临床研究的完整数据已获通过，成为国内首个且唯一获得NMPA完全批准的IgA肾病对因治疗药物。
值得注意的是，4月22日，云顶新耀获得联交所正式批准，将“B”标记从股票代码中移除，这是云顶新耀转向“商业化成熟企业”的重要里程碑，标志著云顶新耀在市值和收入等方面达到了更高标准，商业化能力得到进一步认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.